Thomas Schall, ChemoCentryx CEO (file photo)

Chemo­Cen­tryx plunges as FDA rais­es ques­tions about rare dis­ease drug ahead of ad­comm

Chemo­Cen­tryx’s stock price on Wednes­day was cut in half by the re­lease of FDA brief­ing doc­u­ments ahead of a Thurs­day ad­comm, rais­ing ques­tions on the com­pa­ny’s clin­i­cal da­ta to sup­port ava­co­pan as a treat­ment for adults with a rare and se­ri­ous dis­ease known as an­ti-neu­trophil cy­to­plas­mic au­toan­ti­body (AN­CA)-vas­culi­tis.

AN­CA-as­so­ci­at­ed vas­culi­tides (AAV) af­fect small to medi­um-size blood ves­sels that can be fa­tal in less than a year if left un­treat­ed, ac­cord­ing to FDA. On­ly Roche’s Rit­ux­an is cur­rent­ly FDA-ap­proved for the treat­ment of AAV, while glu­co­cor­ti­coids are ap­proved for the broad­er in­di­ca­tion of vas­culi­tis.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.